Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 217

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme

Izumoto, Shuichi, Tsuboi, Akihiro, Oka, Yoshihiro, Suzuki, Tsuyoshi, Hashiba, Tetsuo, Kagawa, Naoki, Hashimoto, Naoya, Maruno, Motohiko, Elisseeva, Olga A., Shirakata, Toshiaki, Kawakami, Manabu, Oji, Yusuke, Nishida, Sumiyuki, Ohno, Satoshi, Kawase, Ichiro, Hatazawa, Jun, Nakatsuka, Shin-ichi, Aozasa, Katsuyuki, Morita, Satoshi, Sakamoto, Junichi, Sugiyama, Haruo, Yoshimine, Toshiki · 2008 · Journal of Neurosurgery

Abstract

Object: The object of this study was to investigate the safety and clinical responses of immunotherapy targeting the WT1 (Wilms tumor 1) gene product in patients with recurrent glioblastoma multiforme (GBM). Methods: Twenty-one patients with WT1/HLA-A*2402–positive recurrent GBM were included in a Phase II clinical study of WT1 vaccine therapy. In all patients, the tumors were resistant to standard therapy. Patients received intra-dermal injections of an HLA-A*2402–restricted, modified 9-mer WT1 peptide every week for 12 weeks. Tumor size, which was obtained by measuring the contrast-enhanced area on magnetic resonance images, was determined every 4 weeks. The responses were analyzed according to Response Evaluation Criteria in Solid Tumors (RECIST) 12 weeks after the initial vaccination. Patients who achieved an effective response continued to be vaccinated until tumor progression occurred. Progression-free survival and overall survival after initial WT1 treatment were estimated. Results: The protocol was well tolerated; only local erythema occurred at the WT1 vaccine injection site. The clinical responses were as follows: partial response in 2 patients, stable disease in 10 patients, and progressive disease in 9 patients. No patient had a complete response. The overall response rate (cases with complete or partial response) was 9.5%, and the disease control rate (cases with complete or partial response as well as those in which disease was stable) was 57.1%. The median progression-free survival (PFS) period was 20.0 weeks, and the 6-month (26-week) PFS rate was 33.3%. Conclusions: Although a small uncontrolled nonrandomized trial, this study showed that WT1 vaccine therapy for patients with WT1/HLA-A*2402–positive recurrent GBM was safe and produced a clinical response. Based on these results, further clinical studies of WT1 vaccine therapy in patients with malignant glioma are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3171/jns/2008/108/5/0963

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 217

Metadata

Authors
Izumoto, S., Tsuboi, A., Oka, Y., Suzuki, T., Hashiba, T., Kagawa, N., Hashimoto, N., Maruno, M., Elisseeva, O. A., Shirakata, T., Kawakami, M., Oji, Y., Nishida, S., Ohno, S., Kawase, I., Hatazawa, J., Nakatsuka, S.-I., Aozasa, K., Morita, S., Sakamoto, J., Sugiyama, H., & Yoshimine, T.
Venue
Journal of Neurosurgery
Published
2008-05
Volume
108
Issue
5
Pages
963-971
ISSN
  • 0022-3085 (ISSN-L)
  • 1933-0693
OpenAlex
W2082226454
Cited by
217
References
4
FWCI
6.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. https://app.cochat.ai/papers/10.3171/jns/2008/108/5/0963
The paper
Izumoto, S., Tsuboi, A., Oka, Y., Suzuki, T., Hashiba, T., Kagawa, N., Hashimoto, N., Maruno, M., Elisseeva, O. A., Shirakata, T., Kawakami, M., Oji, Y., Nishida, S., Ohno, S., Kawase, I., Hatazawa, J., Nakatsuka, S.-I., Aozasa, K., Morita, S., . . . Yoshimine, T. (2008). Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. Journal of Neurosurgery. https://doi.org/10.3171/jns/2008/108/5/0963

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.